PubRank

Georg Auburger

Author PubWeight™ 83.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004 15.91
2 Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007 5.68
3 Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010 5.26
4 Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012 2.18
5 Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 2006 1.96
6 Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet 2010 1.86
7 Spinocerebellar ataxia 2 (SCA2). Cerebellum 2008 1.84
8 Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol 2012 1.82
9 Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008 1.79
10 Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009 1.71
11 Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol 2013 1.40
12 Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003 1.37
13 Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. J Cell Sci 2010 1.25
14 Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 2011 1.24
15 A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 2010 1.13
16 The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 2011 1.12
17 The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol 2014 1.11
18 Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005 1.09
19 Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A 2011 1.08
20 Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet 2008 1.07
21 Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal 2008 1.06
22 The first genomewide interaction and locus-heterogeneity linkage scan in bipolar affective disorder: strong evidence of epistatic effects between loci on chromosomes 2q and 6q. Am J Hum Genet 2007 1.04
23 Loss of mitochondrial peptidase Clpp leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Hum Mol Genet 2013 1.03
24 Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging 2005 1.02
25 Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol 2008 0.96
26 ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 2012 0.94
27 Prism adaptation in spinocerebellar ataxia type 2. Neuropsychologia 2007 0.91
28 Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol 2006 0.91
29 A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet 2012 0.90
30 Genomewide scan and fine-mapping linkage studies in four European samples with bipolar affective disorder suggest a new susceptibility locus on chromosome 1p35-p36 and provides further evidence of loci on chromosome 4q31 and 6q24. Am J Hum Genet 2005 0.90
31 Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 2010 0.89
32 Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging 2013 0.89
33 Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A. Neurogenetics 2004 0.88
34 DYT7 gene locus for cervical dystonia on chromosome 18p is questionable. Mov Disord 2012 0.87
35 Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. Mov Disord 2007 0.87
36 A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J Neural Transm (Vienna) 2011 0.87
37 ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet 2012 0.86
38 Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol 2004 0.85
39 Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neurosci Lett 2007 0.85
40 Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice. PLoS One 2012 0.84
41 Elastin polymorphism haplotype and intracranial aneurysms are not associated in Central Europe. Stroke 2003 0.84
42 Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J Neural Transm Suppl 2009 0.84
43 The mitochondrial kinase PINK1, stress response and Parkinson's disease. J Bioenerg Biomembr 2009 0.84
44 Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. J Mol Neurosci 2013 0.84
45 Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiol Aging 2011 0.84
46 Sleep disorders in spinocerebellar ataxia type 2 patients. Neurodegener Dis 2011 0.84
47 Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev 2006 0.83
48 Dysregulated expression of lipid storage and membrane dynamics factors in Tia1 knockout mouse nervous tissue. Neurogenetics 2014 0.83
49 Spinocerebellar ataxia type 2 (SCA2): identification of early brain degeneration in one monozygous twin in the initial disease stage. Cerebellum 2011 0.81
50 Mutations in CIZ1 are not a major cause for dystonia in Germany. Mov Disord 2015 0.80
51 Mutations in the lysyl oxidase gene not associated with intracranial aneurysm in central European families. Cerebrovasc Dis 2004 0.79
52 Solving a 50 year mystery of a missing OPA1 mutation: more insights from the first family diagnosed with autosomal dominant optic atrophy. Mol Neurodegener 2010 0.79
53 Intranuclear aggregation of nonexpanded ataxin-3 in marinesco bodies of the nonhuman primate substantia nigra. Exp Neurol 2002 0.79
54 Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum. J Neurosci 2012 0.78
55 Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. Mol Neurobiol 2014 0.78
56 The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics 2014 0.78
57 Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol 2014 0.77
58 Age-Related Changes of 14-3-3 Isoforms in Midbrain of A53T-SNCA Overexpressing Mice. J Parkinsons Dis 2015 0.76
59 Saccadic latency is prolonged in Spinocerebellar Ataxia type 2 and correlates with the frontal-executive dysfunctions. J Neurol Sci 2011 0.76
60 Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis. Depress Anxiety 2009 0.75
61 Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Arch Neurol 2005 0.75